Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 16,859 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Autism Spectrum Disorders
Interventions: Arbaclofen; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 5 Years to 21 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 21 more

Conditions: Keratosis Pilaris
Interventions: Salkera Emollient Foam; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: HIV Infections, Hepatitis C, Hemophilia
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obstructive Sleep Apnea
Interventions: Pixi pediatric mask; Device
Lead sponsor: ResMed; Industry
Eligibility: 2 Years to 7 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Redwood City, California • Aurora, Colorado • Wallingford, Connecticut

Conditions: Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: HIV Infections, Influenza
Interventions: Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more

Conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Daratumumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Low Risk Myelodysplastic Syndromes
Interventions: R906289 Monosodium (R289 Na); Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 10 more

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: MBG453, Azacitidine, Decitabine, INQOVI (oral decitabine); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 12 more

Conditions: Sepsis, Critical Illness, Respiratory Failure, Nutrition Disorders, Calorie Deficiency, Diaphragm Injury, Quadriceps Muscle Atrophy
Interventions: Caloric delivery will target results of IC measurement.; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dry Eye Syndromes
Interventions: M22-IPL; Device
Lead sponsor: Lumenis Be Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Beverly Hills, California • Austin, Texas

Conditions: Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Interventions: Burosumab; Drug
Lead sponsor: Laura Tosi; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Down Syndrome
Interventions: Insulin glulisine, Saline; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 35 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: HIV, Depression, HIV Infections
Interventions: Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD), Life-steps adherence treatment, Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Parkinsonian Syndrome
Interventions: [123I]ß CIT and SPECT imaging; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 22 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: HIV Infections
Interventions: Female condom skills training; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome
Interventions: Guadecitabine; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Buffalo, New York • Durham, North Carolina • Columbus, Ohio + 2 more

Conditions: HIV Infections
Interventions: Ranitidine hydrochloride, Foscarnet sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Antiretroviral Regimens; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 67
States / cities: Fresno, California • Mill Valley, California • Oakland, California + 32 more

Conditions: Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Interventions: Ondansetron, Palonosetron; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Immunodeficiency
Interventions: Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%; Biological
Lead sponsor: Prometic Biotherapeutics, Inc.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 13
States / cities: Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more

Conditions: Immunodeficiency Syndrome, Non-Cancer Diagnosis
Interventions: Alemtuzumab, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation; Biological · Procedure · Drug + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 54 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 6
States / cities: Oakland, California • Cleveland, Ohio • Portland, Oregon + 3 more

Search by objective public record fields.

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study

Treatment of Hepatitis C in Hemophilic Patients With HIV

Pediatric Nasal Mask Usability Study

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Indirect Calorimetry Usage and Effect in Ventilator-free Days and Muscle Thickness in Septic Ventilated Patients

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

Burosumab for CSHS

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

Evaluation of Albuminuria HIV-Infected Patients

Education Program to Promote Female Condom Use

Guadecitabine Extension Study

The Effect of Stomach Acid on Foscarnet

Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders